TY - JOUR
T1 - Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis
AU - Kawano, Shinji
AU - Matsumoto, Kazuaki
AU - Hara, Ryohei
AU - Kuroda, Yuko
AU - Ikawa, Kazuro
AU - Morikawa, Norifumi
AU - Horino, Tetsuya
AU - Hori, Seiji
AU - Kizu, Junko
N1 - Funding Information:
Seiji Hori has received a speaker's honoraria and grant support from Daiichi Sankyo Co., Ltd . All other authors report no conflicts of interest.
Publisher Copyright:
© 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - The pharmacokinetics of meropenem have not yet been examined in Japanese patients receiving Continuous venovenous hemodialysis (CVVHD). The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan. The values of pharmacokinetic parameters were 17.5±5.6l for V1, 1.27±0.38h-1 for K12, 0.71±0.40h-1 for K21 and 0.17±0.02h-1 for K10. Based on these mean parameters (V1, K12, K21 and K10), time above MIC (T>MIC) values were estimated at different MICs using various meropenem regimens. For bacteria with a meropenem MIC of ≤2μg/ml, a dosing regimen of 0.25g every 24h achieved more than 40% T>MIC. For a MIC of 4μg/ml, all the regimens tested, except for 0.25g every 24h, achieved more than 40% T>MIC. For a MIC of 16μg/ml, dosing regimens of 0.5g every 8h, 1g every 12h, and 1g every 8h achieved 40% T>MIC, reaching the pharmacokinetic-pharmacodynamic target range. This is the first study to examine the pharmacokinetics of meropenem under a CVVHD setting in Japan. The pharmacokinetic-pharmacodynamic profile of dosing regimens tested in this study will assist in selecting the appropriate meropenem regimens for patients receiving CVVHD.
AB - The pharmacokinetics of meropenem have not yet been examined in Japanese patients receiving Continuous venovenous hemodialysis (CVVHD). The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan. The values of pharmacokinetic parameters were 17.5±5.6l for V1, 1.27±0.38h-1 for K12, 0.71±0.40h-1 for K21 and 0.17±0.02h-1 for K10. Based on these mean parameters (V1, K12, K21 and K10), time above MIC (T>MIC) values were estimated at different MICs using various meropenem regimens. For bacteria with a meropenem MIC of ≤2μg/ml, a dosing regimen of 0.25g every 24h achieved more than 40% T>MIC. For a MIC of 4μg/ml, all the regimens tested, except for 0.25g every 24h, achieved more than 40% T>MIC. For a MIC of 16μg/ml, dosing regimens of 0.5g every 8h, 1g every 12h, and 1g every 8h achieved 40% T>MIC, reaching the pharmacokinetic-pharmacodynamic target range. This is the first study to examine the pharmacokinetics of meropenem under a CVVHD setting in Japan. The pharmacokinetic-pharmacodynamic profile of dosing regimens tested in this study will assist in selecting the appropriate meropenem regimens for patients receiving CVVHD.
KW - Continuous venovenous hemodialysis
KW - Dosing regimen
KW - Meropenem
KW - Pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=84937761730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937761730&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2015.02.011
DO - 10.1016/j.jiac.2015.02.011
M3 - Article
C2 - 25869915
AN - SCOPUS:84937761730
VL - 21
SP - 476
EP - 478
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 6
ER -
